Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah C Gilbert

Showing results (181-190 of 215) with videos related to

Pageof 22
Sort By:
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
Biotechnology and Bioengineering|September 29, 2021
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needsCarina C D Joe, Jinlin Jiang, Thomas Linke, et al.
The Journal of Infectious Diseases|October 23, 2014
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individualsSusanne H Hodgson, Katie J Ewer, Carly M Bliss, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaquesNeeltje van Doremalen, Teresa Lambe, Alexandra Spencer, et al.
Plos One|July 30, 2011
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909Christopher J A Duncan, Susanne H Sheehy, Katie J Ewer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 24, 2012
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humansSusanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 24, 2006
Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytesSimon P Graham, Roger Pellé, Yoshikazu Honda, et al.
Plos One|March 26, 2013
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsCaroline Ogwang, Muhammed Afolabi, Domtila Kimani, et al.
The Lancet. Infectious Diseases|October 23, 2022
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trialShabir A Madhi, Gaurav Kwatra, Simone I Richardson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 17, 2014
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsDomtila Kimani, Ya Jankey Jagne, Momodou Cox, et al.
Pageof 22

Showing results (181-190 of 215) with videos related to

Sort By:
Pageof 22
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
Biotechnology and Bioengineering|September 29, 2021
Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needsCarina C D Joe, Jinlin Jiang, Thomas Linke, et al.
The Journal of Infectious Diseases|October 23, 2014
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individualsSusanne H Hodgson, Katie J Ewer, Carly M Bliss, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaquesNeeltje van Doremalen, Teresa Lambe, Alexandra Spencer, et al.
Plos One|July 30, 2011
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909Christopher J A Duncan, Susanne H Sheehy, Katie J Ewer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 24, 2012
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humansSusanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 24, 2006
Theileria parva candidate vaccine antigens recognized by immune bovine cytotoxic T lymphocytesSimon P Graham, Roger Pellé, Yoshikazu Honda, et al.
Plos One|March 26, 2013
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsCaroline Ogwang, Muhammed Afolabi, Domtila Kimani, et al.
The Lancet. Infectious Diseases|October 23, 2022
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trialShabir A Madhi, Gaurav Kwatra, Simone I Richardson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 17, 2014
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsDomtila Kimani, Ya Jankey Jagne, Momodou Cox, et al.
Pageof 22